| Project/Area Number |
26860599
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Respiratory organ internal medicine
|
|---|
| Research Institution | Chiba University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
TAKIGUCHI Yuichi
ISHIWATA Tsukasa
EBATA Takahiro
|
|---|
| Project Period (FY) |
2014-04-01 – 2016-03-31
|
| Project Status |
Completed (Fiscal Year 2015)
|
| Budget Amount *help |
¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2014: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Keywords | Sonic Hedgehog pathway / Smoothened / 神経内分泌がん / apoptosis / Gli1 / Gli2 / neuroendocrine carcinoma / Gli-1 / Gli-2 / smoothened / anti apoptosis / cyclopamine |
|---|
| Outline of Final Research Achievements |
Neuroendocrine carcinoma of the lung is a refractory cancer and results in poor survival. However, the standard therapy for patients with advanced neuroendocrine carcinoma of the lung has not been established. We hypothesized that the Sonic Hedgehog (SHH) pathway may play an important role of tumor proliferation and drug resistance and be a new therapeutic target in that cancer. Our study revealed that major signaling factors were expressed in cell lines of neuroendocrine carcinoma of the lung and some inhibitors of the SHH signaling suppressed cell proliferation. In addition, siRNA against Gli1/2 which are major transcription factors in the SHH pathway increased the effect of cisplatin in those cell lines.
|
